(Reuters) - A sales representative for Merck & Co. <MRK.N> filed a more than $100 million sex discrimination lawsuit against the drugmaker on Thursday, claiming that it particularly discriminates against pregnant employees and women with children. Full story
Fitch Ratings said Friday it's affirmed its ratings for Merck & Co., but downgraded its rating outlook for the world's third-biggest drugmaker to "Negative" from "Positive." Full story
During a conference call with analysts to discuss first-quarter results Wednesday, drugmaker Merck & Co. introduced its new head of research and development, Roger Perlmutter, a former Merck research executive who had run R&D at biotech drugmaker Amgen Inc. for more than a decade. Analysts asked Per Full story
The FMHR traders debate how to play Yum! Brands after the company's China sales fell less-than-expected; and Steve Grasso of Stuart Frankel offers his opinion on whether Merck has more upside ahead.
Merck showed big numbers in this morning's earnings report, with CNBC's Seema Mody.
Merck announced results of a study indicating their new drug, suvorexant, made people fall asleep 40 percent faster and 40 percent longer than placebo without a lingering drowsy feeling upon waking. NBC’s Robert Bazell reports.
This undated handout image, provided by Merck & Co. Inc. on March 9, 2009, shows the cholesterol drug Vytorin. REUTERS/Courtesy of Merck/Handout
A branch of drugs and chemicals group Merck is pictured in central German city of Darmstadt March 7, 2012. REUTERS/Alex Domanski
The logo of drugs and chemicals group Merck is pictured at one of its branches in central German city of Darmstadt March 7, 2012. REUTERS/Alex Domanski